PharmaShots | Incisive News in 3 Shots

Subscribe Now

Regeneron

Regeneron Reports Results from P-II (ROXI-VTE-I and ROXI-VTE-II) Trials of REGN7508 and REGN9933 for Venous Thromboembolism

Regeneron Reports Results from P-II (ROXI-VTE-I and ROXI-VTE-II) Trials of REGN7508 and REGN9933 for Venous Thromboembolism

December 20, 2024

Regeneron Reports Data from P-III (QUASAR) Trial of Eylea HD (Aflibercept) in Patients with Macular Edema following Retinal Vein Occlusion

Regeneron Reports Data from P-III (QUASAR) Trial of Eylea HD (Aflibercept) in Patients with Macular Edema following Retinal Vein O...

December 18, 2024

Regeneron and Sanofi Report the US FDA’s sBLA Acceptance of Dupixent (Dupilumab) to Treat Chronic Spontaneous Urticaria (CSU)

Regeneron and Sanofi Report the US FDA’s sBLA Acceptance of Dupixent (Dupilumab) to Treat Chronic Spontaneous Urticaria (CSU)

November 15, 2024

Regeneron’s Ordspono (Odronextamab) Receives the EC’s Approval to Treat R/R Follicular Lymphoma and Diffuse Large B-cell Lymphoma

Regeneron’s Ordspono (Odronextamab) Receives the EC’s Approval to Treat R/R Follicular Lymphoma and Diffuse Large B-cell Lymphoma

August 26, 2024

Regeneron Showcases Updated on BLA for Linvoseltamab to Treat R/R Multiple Myeloma (MM)

Regeneron Showcases Updated on BLA for Linvoseltamab to Treat R/R Multiple Myeloma (MM)

August 21, 2024

Regeneron and Sanofi Report the EC’s Approval of Dupixent to Treat Chronic Obstructive Pulmonary Disease (COPD)

Regeneron and Sanofi Report the EC’s Approval of Dupixent to Treat Chronic Obstructive Pulmonary Disease (COPD)

July 3, 2024

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us